Comment on “KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study”
Titel:
Comment on “KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study”
Auteur:
Hughes, Amy Clarson, Jade Gargett, Tessa Yu, Wenbo Brown, Michael P. Lopez, Angel F. Hughes, Timothy P. Yong, Agnes S.M.